Please assess the completion status of the following clinical trial:

Trial Title: Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* STEMI patients (defined as: Evidence of ischemic chest pain for \>30 minutes within \<12 hours and new ST-segment elevation for ≥2 mm in two or more contiguous electrocardiographic leads or in case of a true posterior infarction reciprocal ST-segment depressions in in V1 and V2 \>1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0 or 1 in the infarct related coronary artery.~Exclusion Criteria:~* Significant liver disease~* Thrombolytic therapy~* History of prior myocardial infarction~* Current atrial fibrillation~* History of congestive heart failure~* History of migraine headache~* Significant valvular heart disease, primary myocardial disease~* Cardiogenic shock (sRR \<90mmHg or need for inotropic support)~* Child-bearing potential~* Inability to read, understand and sign the informed consent~* Life expectancy \<3y~* Prior organ transplantation~* Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives~* Participation in another clinical study~* Metal implants contraindicating CMR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): BQ-123

Based on this trial design, predict the completion outcome and termination type (if applicable).